The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Diagnosis and Treatment of Latent Tuberculosis Infection

잠복결핵감염의 진단과 치료

  • Shim, Tae-Sun (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 심태선 (울산대학교 의과대학 서울아산병원 호흡기내과)
  • Published : 2012.03.01
⟨ Previous Next ⟩

Abstract

In order to control and eliminate tuberculosis (TB), the management of latent TB infection (LTBI) as well as active TB is inevitable. Diagnosis and treatment of LTBI is targeted for high risk individuals for developing TB. High risk groups involve recent contacts with infectious TB patients, subjects with immunosuppressed conditions, and health care personnels. Diagnosis of LTBI is done using tuberculin skin test or recently developed ex-vivo interferon-gamma releasing assays after excluding active TB clinically. The main LTBI treatment regimen is 9 months of isoniazid treatment, and additional regimens include rifampicin monotherapy (4 months in adults and 6 months in children) or a combined regimen of isoniazid and rifampicin for 3 months.

Keywords

References

  1. Choi CM, Kang CI, Kim DH, et al. The role of TST in the diagnosis of latent tuberculosis infection among military personnel in South Korea. Int J Tuberc Lung Dis 2006; 10:1342-1346.
  2. Lee JY, Choi HJ, Park IN, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006; 28:24-30. https://doi.org/10.1183/09031936.06.00016906
  3. Joint Committee for the Development of Korean Guidelines for Tuberculosis; Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 2011.
  4. Shim T. Diagnosis of latent tuberculosis infection. Medical review 2011;8:31-35.
  5. Shim T. Treatment of latent tuberculosis infection. Medical review 2011;8:22-25.
  6. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010;59(RR-5):1-25.
  7. National Institute for Health, Clinical Excellence (NICE). Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control [Internet]. London: NICE, c2006 [cited 2007 Jan 5]. Available from: http://www.nice.org.uk/page.aspx?o=296657.
  8. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002;57:804-809. https://doi.org/10.1136/thorax.57.9.804
  9. Canadian Tuberculosis Committee. Recommendations on interferon gamma release assays for the diagnosis of latent tuberculosis infection-2010 update. CCDR Canada Communicable Disease Report 2010;36:1-21.
  10. Takahashi H, Shigehara K, Yamamoto M, et al. Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int 2007;27:1143-1148. https://doi.org/10.1007/s00296-007-0361-2
  11. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008; 35:1271-1276.
  12. Chang B, Park HY, Jeon K, et al. Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol 2011;30:1535-1541. https://doi.org/10.1007/s10067-011-1771-9
  13. Song S, Jeon D, Kim JW, et al. Performance of confirmatory interferon-gamma release assay in school tuberculosis outbreaks. Chest 2011 Oct 6 [Epub]. http://dx.doi.org/10.1378/chest.11-1158.
  14. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161(4 Pt 2):S221-S247.
  15. Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian Refugees: a five-year surveillance study. Am Rev Respir Dis 1988;137:805-809. https://doi.org/10.1164/ajrccm/137.4.805
  16. Grzybowski S, Fishaut H, Rowe J, Brown A. Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service. Am Rev Respir Dis 1971;104:605-608.
  17. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-850.
  18. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong: Hong Kong Chest Service/ Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992;145:36-41. https://doi.org/10.1164/ajrccm/145.1.36
  19. Polesky A, Farber HW, Gottlieb DJ, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996;154:1473-1477. https://doi.org/10.1164/ajrccm.154.5.8912767
  20. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3-and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715-722. https://doi.org/10.1086/520983
  21. Rennie TW, Bothamley GH, Engova D, Bates IP. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J 2007;30:728-735. https://doi.org/10.1183/09031936.00034007
  22. Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011;60:1650-1653.
  23. Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006;173:922-926. https://doi.org/10.1164/rccm.200512-1953OC
  24. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011;365:11-20. https://doi.org/10.1056/NEJMoa1005136
  25. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-2166. https://doi.org/10.1056/NEJMoa1104875
  26. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep 1992;41(RR-11):61-71.

Cited by

  1. 우리나라 잠복결핵감염 검진전략의 경제성 분석 vol.23, pp.4, 2013, https://doi.org/10.4332/kjhpa.2013.23.4.349
  2. The Usefulness of the Tuberculosis Skin Test and the Interferon-gamma Release Assay in the Diagnosis of Latent Tuberculosis Infection in South Korea vol.5, pp.suppl, 2012, https://doi.org/10.1016/j.phrp.2014.10.009
  3. 대학생 잠복결핵 감염의 진단 vol.48, pp.3, 2016, https://doi.org/10.15324/kjcls.2016.48.3.225
  4. Tracheal pleomorphic adenoma with coexisting pulmonary tuberculoma vol.35, pp.1, 2018, https://doi.org/10.12701/yujm.2018.35.1.114